Flosequinan | CAS#76568-02-0 | vasodilator

MedKoo Cat#: 584288 | Name: Flosequinan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Flosequinan is an arteriovenous vasodilator that has shown to be effective for the treatment of acute heart failure.

Chemical Structure

Flosequinan

CAS#76568-02-0

Theoretical Analysis

MedKoo Cat#: 584288

Name: Flosequinan

CAS#: 76568-02-0

Chemical Formula: C11H10FNO2S

Exact Mass: 239.0416

Molecular Weight: 239.26

Elemental Analysis: C, 55.22; H, 4.21; F, 7.94; N, 5.85; O, 13.37; S, 13.40

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Flosequinan

IUPAC/Chemical Name

4(1H)-Quinolinone, 7-fluoro-1-methyl-3-(methylsulfinyl)-

InChi Key

UYGONJYYUKVHDD-UHFFFAOYSA-N

InChi Code

InChI=1S/C11H10FNO2S/c1-13-6-10(16(2)15)11(14)8-4-3-7(12)5-9(8)13/h3-6H,1-2H3

SMILES Code

O=C1C(S(C)=O)=CN(C)C2=C1C=CC(F)=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 239.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yano M, Kohno M, Yamamoto T, Hisaoka T, Tanigawa T, Ono K, Lee B, Konishi M, Matsuzaki M. Effects of balanced vasodilator, flosequinan, on aortic impedance in failing heart. J Cardiovasc Pharmacol. 1998 Sep;32(3):466-70. PubMed PMID: 9733361. 2: Cavero PG, De Marco T, Kwasman M, Lau D, Liu M, Chatterjee K. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure. J Am Coll Cardiol. 1992 Dec;20(7):1542-8. PubMed PMID: 1452928. 3: Kashiyama E, Yokoi T, Todaka T, Odomi M, Kamataki T. Chiral inversion of drug: role of intestinal bacteria in the stereoselective sulphoxide reduction of flosequinan. Biochem Pharmacol. 1994 Jul 19;48(2):237-43. PubMed PMID: 8053920. 4: Sim MF, Yates DB, Parkinson R, Cooling MJ. Cardiovascular effects of the novel arteriovenous dilator agent, flosequinan in conscious dogs and cats. Br J Pharmacol. 1988 Jun;94(2):371-80. PubMed PMID: 3293682; PubMed Central PMCID: PMC1854003. 5: Kessler PD, Packer M, Medina N, Yushak M. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure. J Cardiovasc Pharmacol. 1988 Jul;12(1):6-11. PubMed PMID: 2459536. 6: Miao L, Perreault CL, Travers KE, Morgan JP. Mechanisms of positive inotropic action of flosequinan, hydralazine, and milrinone on mammalian myocardium. Eur J Pharmacol. 1997 Feb 26;321(2):201-8. PubMed PMID: 9063689. 7: Silke B, Tennet H, Fischer-Hansen J, Keller N, Heikkila J, Salminen K. A double-blind, parallel-group comparison of flosequinan and enalapril in the treatment of chronic heart failure. Eur Heart J. 1992 Aug;13(8):1092-100. PubMed PMID: 1505560. 8: Kashiyama E, Yokoi T, Odomi M, Kamataki T. Stereoselective S-oxidation and reduction of flosequinan in rat. Xenobiotica. 1999 Aug;29(8):815-26. PubMed PMID: 10553722. 9: Elborn JS, Stanford CF, Nicholls DP. Effect of flosequinan on exercise capacity and symptoms in severe heart failure. Br Heart J. 1989 Apr;61(4):331-5. PubMed PMID: 2653391; PubMed Central PMCID: PMC1216672. 10: Elborn JS, Riley M, Stanford CF, Nicholls DP. The effects of flosequinan on submaximal exercise in patients with chronic cardiac failure. Br J Clin Pharmacol. 1990 May;29(5):519-24. PubMed PMID: 2112405; PubMed Central PMCID: PMC1380150. 11: Cowley AJ, McEntegart DJ, Hampton JR, Barnett DB, Bexton RS, Boyle R, Hanley SP, Millar-Craig M, Morris GK, Nicholls AJ, et al. Long-term evaluation of treatment for chronic heart failure: a 1 year comparative trial of flosequinan and captopril. Cardiovasc Drugs Ther. 1994 Dec;8(6):829-36. PubMed PMID: 7742261. 12: Weishaar RE, Wallace AM, Kiser LM, Ferraris VA, Britton LW 2nd, Sim MF. Assessment of flosequinan's direct effect on human arterial, venous, and cardiac muscle: comparison with other classes of agents used to treat heart failure. J Cardiovasc Pharmacol. 1994 May;23(5):792-8. PubMed PMID: 7521463. 13: Cowley AJ, McEntegart DJ. Placebo-controlled trial of flosequinan in moderate heart failure. The possible importance of aetiology and method of analysis in the interpretation of the results of heart failure trials. Int J Cardiol. 1993 Feb;38(2):167-75. PubMed PMID: 8454379. 14: Schneeweiss A, Wynne RD, Marmor A. The effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction. Jpn Heart J. 1989 Sep;30(5):627-34. PubMed PMID: 2614925. 15: Sakai M, Ohkawa S, Kaku T, Kuboki K, Chida K, Imai T. Pharmacokinetics of flosequinan in elderly patients with chronic congestive heart failure. Eur J Clin Pharmacol. 1993;44(4):387-9. PubMed PMID: 8513852. 16: Jones RB, Frodsham G, Dickinson K, Foster GA. Effect of flosequinan on ischaemia-induced arrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat. Br J Pharmacol. 1993 Apr;108(4):1111-6. PubMed PMID: 8097953; PubMed Central PMCID: PMC1908168. 17: Kamali F, Edwards C. Conversion of flosequinan to the sulphone metabolite in subcellular fractions of human liver, in-vitro. J Pharm Pharmacol. 1993 Jun;45(6):578-80. PubMed PMID: 8103111. 18: Riegger GA, Kahles H, Wagner A, Kromer EP, Elsner D, Kochsiek K. Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure. Cardiovasc Drugs Ther. 1990 Oct;4(5):1395-402. PubMed PMID: 1980598. 19: Bartels GL, Remme WJ, Look MP, Kruijssen DA. Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure. J Card Fail. 1995 Mar;1(2):117-25. PubMed PMID: 9420641. 20: Dakak N, Makhoul N, Merdler A, Yechiely H, Kahana L, Halon DA, Schneeweiss A, Lewis BS. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy. Eur Heart J. 1993 Jun;14(6):836-44. PubMed PMID: 8325314.